Biogen Inc.

NasdaqGS:BIIB Stock Report

Market Cap: US$31.8b

Biogen Valuation

Is BIIB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIIB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: BIIB ($215.5) is trading below our estimate of future cash flow value ($447.94)

Significantly Below Future Cash Flow Value: BIIB is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIIB?

Key metric: As BIIB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BIIB. This is calculated by dividing BIIB's market cap by their current earnings.
What is BIIB's PE Ratio?
PE Ratio38.2x
EarningsUS$834.60m
Market CapUS$31.84b

Price to Earnings Ratio vs Peers

How does BIIB's PE Ratio compare to its peers?

The above table shows the PE ratio for BIIB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.9x
INCY Incyte
15.8x-5.13%US$25.4b
UTHR United Therapeutics
16.2x15.60%US$21.2b
ALNY Alnylam Pharmaceuticals
41.4x23.37%US$32.1b
REGN Regeneron Pharmaceuticals
18.1x11.98%US$78.4b
BIIB Biogen
38.2x21.41%US$31.8b

Price-To-Earnings vs Peers: BIIB is expensive based on its Price-To-Earnings Ratio (38.2x) compared to the peer average (22.9x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does BIIB's PE Ratio compare vs other companies in the US Biotechs Industry?

17 CompaniesPrice / EarningsEstimated GrowthMarket Cap
VOR Vor Biopharma
2x-29.05%US$1.27b
RIGL Rigel Pharmaceuticals
2.7x-13.03%US$871.23m
AGEN Agenus
3.8x-59.69%US$353.41m
VXRT Vaxart
3.1x-29.75%US$118.19m
BIIB 38.2xIndustry Avg. 18.1xNo. of Companies17PE01632486480+
17 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BIIB is expensive based on its Price-To-Earnings Ratio (38.2x) compared to the US Biotechs industry average (18.1x).

Price to Earnings Ratio vs Fair Ratio

What is BIIB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIIB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio38.2x
Fair PE Ratio29x

Price-To-Earnings vs Fair Ratio: BIIB is expensive based on its Price-To-Earnings Ratio (38.2x) compared to the estimated Fair Price-To-Earnings Ratio (29x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BIIB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$215.50
US$238.18
+10.53%
10.89%US$300.00US$175.00n/a31
Sep ’27US$216.04
US$236.22
+9.34%
11.78%US$300.00US$165.00n/a31
Aug ’27US$202.95
US$234.35
+15.47%
11.99%US$300.00US$157.00n/a31
Jul ’27US$209.74
US$220.28
+5.03%
13.57%US$300.00US$150.00n/a31
Jun ’27US$192.23
US$219.44
+14.16%
13.81%US$300.00US$150.00n/a29
May ’27US$187.06
US$217.03
+16.02%
12.94%US$275.00US$150.00n/a29
Apr ’27US$183.78
US$207.03
+12.65%
14.19%US$275.00US$150.00n/a30
Mar ’27US$191.82
US$205.67
+7.22%
13.47%US$260.00US$143.00n/a30
Feb ’27US$179.89
US$193.00
+7.29%
14.50%US$260.00US$143.00n/a29
Jan ’27US$175.99
US$182.07
+3.45%
17.48%US$260.00US$130.00n/a29
Dec ’26US$177.78
US$178.76
+0.55%
18.72%US$260.00US$130.00n/a29
Nov ’26US$154.27
US$174.45
+13.08%
19.94%US$260.00US$118.00n/a29
Oct ’26US$154.22
US$170.72
+10.70%
22.32%US$260.00US$118.00n/a29
Sep ’26US$132.22
US$169.44
+28.15%
23.11%US$260.00US$118.00US$216.0428
Aug ’26US$131.95
US$169.71
+28.62%
23.56%US$260.00US$115.00US$202.9530
Jul ’26US$130.07
US$172.20
+32.39%
23.87%US$260.00US$115.00US$209.7431
Jun ’26US$129.79
US$171.95
+32.48%
23.77%US$260.00US$115.00US$192.2331
May ’26US$120.93
US$179.42
+48.36%
26.99%US$300.00US$115.00US$187.0630
Apr ’26US$132.03
US$200.12
+51.57%
28.64%US$342.00US$135.00US$183.7830
Mar ’26US$140.50
US$201.18
+43.19%
28.19%US$342.00US$135.00US$191.8230
Feb ’26US$143.93
US$228.33
+58.64%
24.77%US$342.00US$138.00US$179.8929
Jan ’26US$152.92
US$244.40
+59.82%
22.10%US$342.00US$164.00US$175.9929
Dec ’25US$160.63
US$254.28
+58.30%
17.78%US$342.00US$184.00US$177.7829
Nov ’25US$173.79
US$255.67
+47.12%
16.80%US$342.00US$180.00US$154.2730
Oct ’25US$190.80
US$270.19
+41.61%
13.67%US$342.00US$190.00US$154.2230
Sep ’25US$204.76
US$271.42
+32.56%
12.99%US$342.00US$190.00US$132.2230
US$238.18
Fair Value
9.5% undervalued intrinsic discount
31
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/20 00:52
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biogen Inc. is covered by 61 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Brian SkorneyBaird
James BirchenoughBarclays